ESR1 and breast cancer: Although this study has limitations, such as the small sample size, the mono-institutional enrollment, and ESR1 status assessment in a single laboratory, our results showed high concordance rate between tumor tissue and ctDNA (91%), providing evidence of reliability and feasibility of liquid biopsy to analyze ESR1 mutation in breast cancer patients.